Ombitasvir/ Paritaprevir/ Ritonavir

Basit Öğe Kaydı
dc.authoridCelik, Ilhami/0000-0002-2604-3776
dc.authoridTurkoglu Yılmaz, Emine/0000-0003-4418-4692
dc.authoridBinay, Umut Devrim/0000-0003-3841-9109
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDemirturk, Nese
dc.contributor.authorYildiz, Orhan
dc.contributor.authorCelik, Ilhami
dc.contributor.authorGuzel, Deniz Kamalak
dc.contributor.authorErsoz, Guelden
dc.contributor.authorBatirel, Ayse
dc.date.accessioned2025-01-27T21:19:51Z
dc.date.available2025-01-27T21:19:51Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: Objective: Ombitasvir/paritaprevir/ritonavir (OMV/PTV/r) + ribavirin (RBV) combination improved the efficacy, safety, and tolerability of the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. We described the effectiveness and safety of OMV/PTV/r + RBV therapy in patients with genotype 4 infection. Materials and Methods: In this prospective cohort study, HCV genotype 4-infected patients treated with OMV/PTV/r + RBV (n=55) who were registered in a national database were included. Study patients were treatment-naive or interferon plus RBV-experienced with or without compensated cirrhosis. Demographic, clinical and virological data were analyzed. Details of clinical and laboratory adverse events (AEs) were recorded.Results: The mean age of the patients was 55.2, and 52.7% were male. The majority of patients were non-cirrhotic (81.8%), and 69.1% were treatment-naive. The HCV RNA level was below 800.000 IU/mL in 16 of the cases. Seventy-eight percent of the patients had an underlying disease. SVR12 rate was 98% in all patients. One patient had virological failure. HCV RNA was undetectable at treatment week 4 in 77.6%, at treatment week 8 in 100%, and at end of treatment in 98%. The SVR12 rates were 100% and 88.9% for those without or with compensated cirrhosis (p= 0.176). Rates of AEs and AEsassociated treatment discontinuation were 69.1% and 3.6% in the patients, respectively.Conclusion: The OBV/PTV/r + RBV combination was found to have high efficacy and safety profile in the patients with chronic HCV genotype 4 infection.
dc.identifier.doi10.36519/idcm.2019.19014
dc.identifier.endpage106
dc.identifier.issn2667-646X
dc.identifier.issue2
dc.identifier.startpage97
dc.identifier.urihttps://doi.org/10.36519/idcm.2019.19014
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28751
dc.identifier.volume1
dc.identifier.wosWOS:001145995100003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherDoc Design Informatics Co Ltd
dc.relation.ispartofInfectious Diseases and Clinical Microbiology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.titleOmbitasvir/ Paritaprevir/ Ritonavir
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu